These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 27276999)
1. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999 [TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. Hammond FM; Sauve W; Ledon F; Davis C; Formella AE PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412 [TBL] [Abstract][Full Text] [Related]
3. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212 [TBL] [Abstract][Full Text] [Related]
4. Dextromethorphan/quinidine for the treatment of pseudobulbar affect. Patatanian E; Casselman J Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895 [TBL] [Abstract][Full Text] [Related]
5. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507 [TBL] [Abstract][Full Text] [Related]
6. Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. Zorowitz RD; Alexander DN; Formella AE; Ledon F; Davis C; Siffert J PM R; 2018 Jun; ():. PubMed ID: 29964212 [TBL] [Abstract][Full Text] [Related]
7. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA; Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150 [TBL] [Abstract][Full Text] [Related]
8. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect. Pioro EP Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221 [TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A; Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036 [TBL] [Abstract][Full Text] [Related]
11. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Yang LP; Deeks ED Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446 [TBL] [Abstract][Full Text] [Related]
12. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. Haiman G; Pratt H; Miller A J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644 [TBL] [Abstract][Full Text] [Related]
13. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. Fralick M; Sacks CA; Kesselheim AS JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect. Miller A; Panitch H J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820 [TBL] [Abstract][Full Text] [Related]
16. Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? Stahl SM CNS Spectr; 2016 Dec; 21(6):419-423. PubMed ID: 27855728 [TBL] [Abstract][Full Text] [Related]
17. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847 [TBL] [Abstract][Full Text] [Related]
18. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. Wahler RG; Reiman AT; Schrader JV J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Schoedel KA; Morrow SA; Sellers EM Neuropsychiatr Dis Treat; 2014; 10():1161-74. PubMed ID: 25061302 [TBL] [Abstract][Full Text] [Related]
20. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study. Berkovich RR; Sokolov AY; Togasaki DM; Yakupova AA; Cesar PH; Sahai-Srivastava S Clin Neuropharmacol; 2018; 41(2):64-69. PubMed ID: 29474194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]